Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Kidney transplants/new amyloidosis study/pomalidomide update

Home/News, Research/Kidney transplants/new amyloidosis study/pomalidomide update

Kidney transplants/new amyloidosis study/pomalidomide update

Here are some important odds ‘n ends that I’ve been saving for a while.  First, a question for my readers:

The Myeloma Beacon just ran an article about whether myeloma patients should be allowed to undergo kidney transplants.  Anyone out there know the guidelines for doing the same here in the United States?  If you do, please let us know.

One thing I do know–staying on dialysis indefinitely is inconvenient, uncomfortable and dangerous.

Those of you that are interested in amyloidosis may want to check this out:

Millennium starts Phase 3 trial for amyloidosis

Millennium: The Takeda Oncology Company began a second Phase 3 trial on its drug candidate which is already being tested on blood cancer, this time to treat the most common form of amyloidosis, a group of diseases resulting from abnormal deposits of certain proteins.

Cambridge-based Millennium, the oncology division of Takeda Pharmaceutical Company Limited, said on Friday that it’s beginning Tourmaline-AL1, a pivotal trial on MLN9708, an inhibitor of cells which break down proteins, in conjunction with the steroid, dexamethasone. The trials will be in patients with light chain amyloidosis – in which antibodies produce abnormal protein fibers which build up on organs, damaging them – which hasn’t responded to other treatments or has come back after treatment…

Good!  Hope it works.  CLICK-HERE to read more.

Finally, I saved this press release from a few weeks back.  It features a quote good friend of mine, Don Wright, as well as news about the the Tackle Cancer Foundation and it’s founders, Elijah Alexander, and his wife, Kimberly.

I met Elijah and Kim four years ago in Boston.  Elijah passed away two years ago.  But Kim has kept his dream of helping inner city myeloma patients alive.

Pomalidomide, Being Tested for Multiple Myeloma, Improves Overall Survival in Patients in a Clinical Trial

 DALLAS, Oct 24, 2012 (BUSINESS WIRE) — Leaders of the Tackle Cancer Foundation today said there’s hopeful news for patients with myeloma, a cancer of cells in the bone marrow. An experimental drug called pomalidomide improved survival longer than a comparison treatment in patients taking part in an international clinical trial.

“I’ve been running marathons while diagnosed with multiple myeloma for the past nine years, and for half that time I’ve been on pomalidomide as part of a clinical trial,” said Don Wright, the 71-year-old marathon runner who heads up the E-Race Cancer Campaign sponsored by Tackle Cancer. “I know first-hand what it means to be on an oral drug that leaves me free to run marathons all over the country while it keeps my cancer at bay. I’m pleased these findings show I’m not alone in benefiting from this investigational new drug.”

The Tackle Cancer Foundation helps pay living expenses for parents who have a child with cancer, and the foundation donates money to support myeloma research. Kimberly Alexander runs Tackle Cancer in memory of her late husband, former NFL football player Elijah Alexander.

Kimberly says, “We know from personal experience how important it is for patients to get treatments that allow them to live active, productive lives. We are pleased to see experimental drugs like pomalidomide showing promise.”

Elijah Alexander, a former NFL football player was diagnosed with multiple myeloma at age 35, much younger than the typical patient profile. Elijah experienced the benefits of new drug development first hand. But multiple myeloma cannot be cured, remissions end, and patients need new options. In clinical trials pomalidomide has been shown to be effective even after other treatments have stopped working. It has been submitted for approval to the US Food and Drug Administration with a decision no later than February 10th.

ABOUT THE TACKLE CANCER FOUNDATION

The Tackle Cancer Foundation helps pay family utility bills up to $2500 per year. A portion of the proceeds goes to the International Myeloma Foundation for research. More information about TCF can be found at www.tacklecancerfoundation.org

Information about E-Race Cancer is available at www.facebook.com/ERACECANCER

SOURCE: The Tackle Cancer Foundation

I’m sure that I speak for a number of my fellow patients when I say we all have great hopes for pomalidomide (Actimid).  It has certainly worked well for Don, as well as a number of other myeloma survivors that I also know well.

It should be available soon.  Keep your fingers crossed!

Feel good and keep smiling!  Pat